AstraZeneca Appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D
Position
Executive Vice President, Development
Company
AstraZeneca Plc
CambridgeBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Sharon will succeed Mene Pangalos, who is retiring and will step down from his role early next year, after almost fourteen years with the company and an illustrious 35-year career. Sharon has been Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca’s rare disease group, since 2013. In this role she has been responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, rare disease diagnostics and bioinformatics supporting Alexion’s industry-leading rare disease pipeline from target discovery through post-marketing
Quick answer
AstraZeneca Appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D (July 28, 2023). AstraZeneca Plc is based in Cambridge, England, United Kingdom.
- Who is the new Executive Vice President, Development at AstraZeneca Plc?
- AstraZeneca Plc named Sharon Barr Executive Vice President, Development, announced July 28, 2023.
- What did AstraZeneca Plc announce on July 28, 2023?
- AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Sharon will succeed Mene Pangalos, who is retiring and will step down from his role early next year, after almost fourteen years with the company and an illustrious 35-year career.
- What does AstraZeneca Plc do?
- AstraZeneca is a global, science-led biopharmaceutical company.
- Where is AstraZeneca Plc based?
- AstraZeneca Plc is based in Cambridge, England, United Kingdom.
- Which similar companies made leadership changes around the same time?
- Pfizer (July 27, 2023), Acadia Pharmaceuticals (July 25, 2023), LumaBridge (August 8, 2023) and Arbutus (July 11, 2023) also announced leadership changes within 45 days of AstraZeneca Plc.
Source: Fundz verified event record.
Other recent leadership changes in Pharmaceutical and Biopharma
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Pfizer (PFE) Appoints Chris Boshoff as Chief Oncology Research and Development Officer (July 27, 2023)
- Acadia Pharmaceuticals Appoints Kevin Oliver Chief Business Officer (July 25, 2023)
- Amanda Ferrier Joins LumaBridge as Chief Operating Officer (August 8, 2023)
- Arbutus Biopharma appoints Karen Sims as chief medical officer (NASDAQ:ABUS) | Seeking Alpha (July 11, 2023)
- MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., (July 10, 2023)
- Vistagen Appoints Cindy Anderson as Chief Financial Officer (August 22, 2023)
Who to call at AstraZeneca Plc, and when
A new leader at AstraZeneca Plc brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day AstraZeneca Plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AstraZeneca Plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AstraZeneca Plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AstraZeneca Plc changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
AstraZeneca Plc changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.